Independent
Tenure on this board
2.5 yrs
Also a director at
Rapport Therapeutics Inc (RAPP)Bioage Labs Inc (BIOA)Seaport Therapeutics Inc (SPTX)
Meeting calendar
AVBP · Annual meeting · Thursday, June 18, 2026
Arrivent Biopharma Inc
3 nominees · 2 ballot items.
Election of three directors for three-year terms; Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026.
Market cap
$1.5B
1Y TSR
+56.0%
Board grade
C-
Record date
Apr 21, 2026
Filing
DEF 14A
Meeting concluded · Jun 18, 2026
Follow how the vote landed and what changed on Arrivent Biopharma Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect three directors (James Healy, M.D., Ph.D.; John Hohneker, M.D.; and Stuart Lutzker, M.D., Ph.D.) to the board for three-year terms expiring in 2029.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
More detail
The proposal asks shareholders to ratify the audit committee’s appointment of PricewaterhouseCoopers LLP as ArriVent’s independent registered public accounting firm for fiscal year 2026. Management and the audit committee selected PwC after reviewing independence considerations and commercial relationships and concluded PwC’s independence is uncompromised. The company frames this vote as a governance check—seeking shareholder input though the audit committee retains the discretion to change auditors if needed. Context includes a transition from KPMG to PwC earlier in 2025 and disclosure of audit fees and services rendered; the audit committee has pre-approval processes for audit and non-audit services. The board recommends a vote FOR the ratification, stating that such ratification reflects good corporate governance, and notes that failure to ratify would prompt reconsideration by the audit committee. Given auditor independence was evaluated and PwC has billed audit fees for 2025, the proposal is routine but important for oversight; institutional investors typically support auditor ratification unless there are known independence concerns.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
2.2 yrs
Also a director at
Curis Inc (CRIS)
Not independent
Tenure on this board
2.5 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 9.4% | 4,401,083 | $102M |
| 2 | INFINITUM ASSET MANAGEMENT, LLC | 8.9% | 4,148,923 | $96M |
| 3 | HHLR ADVISORS, LTD. | 8.4% | 3,929,117 | $91M |
| 4 | ORBIMED ADVISORS LLCActivist | 6.5% | 3,027,328 | $70M |
| 5 | FMR LLC | 5.5% | 2,567,522 | $59M |
| 6 | Octagon Capital Advisors LP | 4.2% | 1,971,054 | $45M |
| 7 | Novo Holdings A/S | 4.2% | 1,942,142 | $45M |
| 8 | Sofinnova Investments, Inc. | 3.6% | 1,696,752 | $39M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 1,528,893 | $35M |
| 10 | General Catalyst Group Management, LLC | 3.2% | 1,494,786 | $34M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Arrivent Biopharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.3B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$724M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$428M
Reference
Frequently asked questions
- When is the Arrivent Biopharma Inc 2026 annual meeting?
- Arrivent Biopharma Inc (AVBP) holds its 2026 annual shareholder meeting on Thursday, June 18, 2026.
- What is the record date for the Arrivent Biopharma Inc 2026 meeting?
- The record date for the Arrivent Biopharma Inc 2026 meeting is Tuesday, April 21, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Arrivent Biopharma Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Arrivent Biopharma Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Arrivent Biopharma Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Arrivent Biopharma Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.